Exclusive Market Insight & Professional Analysis The most comprehensive resource center for the biotech industry

        Sign Up Today: Get Started, and get all the insight you want
  • Exclusive Posts

  • Industry Newsletters

  • Clinical Trials

  • Therapeutic Vaccines

  • Development-Stage Firm

  • Genomics

  • Gene Analysis

  • RNA Analysis

  • Possible Approvals

  • Stock Table

  • Possible Takeovers

  • Technology of the Week

  • Prohost Picks

  • And much more...

PROHOST NEWS AND COMMENTS

GILEAD: HARVONI WILL BE THE BLOCKBUSTER WE EXPECT

  Monday, October 13, 2014

A lot of talk, writings and insinuations were, and still are filling the media prior to, and following the FDA granting Gilead (GILD) approval for its all-oral HCV combination pill Harvoni. All that has been mentioned to date is questionable, except the fact that people infected with genotype 1a and 1b hepatitis C virus will no more suffer the side effects of the old oral drug ribovirin and injectable drug pegylated interferon alpha and, more important, the dreadful complications of hepatitis C viral infection.       More...

TOKAI A NEW COMMER TO THE BIOTECHNOLOGY MARKET

  Thursday, September 18, 2014

TOKAI (TKAI) More...

JAKAFI REGRAWS HAIR IN ALOPECIA AREATA. THE DRUG BELONGS TO INCYTE

  Tuesday, August 19, 2014

 More...

OUR REASONS DIFFER INVESTING IN NKTR

  Monday, August 04, 2014

What’s In the Agenda? Technically-oriented analysts sometimes boost small development-stage stocks on news that are not what we meant to hear when we picked these firms to invest in. Although we appreciate the rallying of stocks for whatever reasons, our choice of firms for investment purpose  is based primarily on their validated far-reaching technologies; their pipeline promising products and the professionalism of their management teams.     More...

INOVIO: PROMISING RESULTS OF THE FIRM VGX-3100 HPV THERAPEUTIC VACCINE

  Wednesday, July 30, 2014

INOVIO More...

EXELIXIS: TIME FOR TRANSFORMATION. THE BEST IS YET TO COME

  Wednesday, July 16, 2014

We stayed with Exelixis (EXEL) In spite of the negative articles that made this firm look as if planting seeds in the ocean. Investors acted as if condemning the firm’s efforts, its small molecule drug design technology and its investigational oncology products. We remained fans in spite of the complete paralysis of the stock for a long time. We always believed that all the negatives about this firm measure little compared to its positives. More...

JAZZ PHARMACEUTICALS: WHY INVESTORS EXCITEMENT?

  Monday, July 07, 2014

Jazz Pharmaceuticals’ (JAZZ) surged following the announcement that it has signed a definitive agreement with Sigma-Tau Pharmaceuticals to acquire the rights for the Americas to the drug defibrotide. JAZZ gained $10 on Wednesday July 2 and added another $0.80 on Thursday July 3 after a brief profit taking. The stock ended the week of the 4th of July trading at $162.82, rebounding from a selloff resulting from analysts’ downgrades in the name of stock price correction.     More...

WOULD YOU BET ON GALENA BIOPHARMA NEUVAX VACCINE NOW?

  Thursday, June 12, 2014

 More...

ARRAY GOOD NEWS AND BIOCRYST OFFERING

  Wednesday, May 28, 2014

ARRAY (ARRY) More...

INTERMUNE OFFERS COMPASSIONATE TREATMENT FOR PATIENTS WITH IDEOPATHIC PULMONARY FIBROSIS V

  Friday, May 16, 2014

 More...

Join our FREE Email Updates, with the latest insight information about the biotech industry